Syncom Formulations (India) growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr3 yr
Revenue+5.2%+29.7%
EBITDA+43.1%+58.0%
Net Income+54.7%+56.1%
EPS (adj.)+54.7%+56.1%
Total Assets+29.2%+12.2%
Total Equity+21.3%+17.5%
Free Cash Flow+244.7%—
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SYNCOMF₹20.33

Syncom Formulations (India) Limited

· Pharma & Health
₹ CrorePeersHESTERBIONGLFINEWINDLASJAGSNPHARMAMRUTANJANINDOCOSAIPARENTMcap ₹1,911 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
3Y
CAGR
Revenue+5.2+29.7
EBITDA+43.1+58.0
Net Income+54.7+56.1
EPS (adj.)+54.7+56.1
Total Assets+29.2+12.2
Total Equity+21.3+17.5
Free Cash Flow+244.7—
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.